New Zealand - English - Medsafe (Medicines Safety Authority)

bradleys pharmaceuticals - coal tar solution 5% - topical cream - 5 % - active: coal tar solution 5% excipient: cetostearyl alcohol chlorocresol liquid paraffin purified water sodium laurilsulfate white soft paraffin

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - acetazolamide 250mg;   - tablet - 250 mg - active: acetazolamide 250mg   excipient: calcium hydrogen phosphate dihydrate magnesium stearate povidone sodium starch glycolate starch - for adjunctive treatment of: oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - drospirenone 3 mg (pink tablet); ethinylestradiol 0,02 mg (pink tablet); placebo (white tablet) - film-coated tablet - 0,02 mg - 3 mg - ethinylestradiol 0.02 mg; drospirenone 3 mg; placebo - drospirenone and ethinylestradiol

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - tamsulosin hydrochloride (unii: 11sv1951mr) (tamsulosin - unii:g3p28oml5i) - tamsulosin hydrochloride 0.4 mg - tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph) [see clinical studies (14)] . tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension. tamsulosin hydrochloride capsules are contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of tamsulosin hydrochloride capsules. reactions have included skin rash, urticaria, pruritus, angioedema, and respiratory symptoms [see adverse reactions (6.2)]. teratogenic effects, pregnancy category b. administration of tamsulosin hydrochloride to pregnant female rats at dose levels up to approximately 50 times the human therapeutic auc exposure (300 mg/kg/day) revealed no evidence of harm to the fetus. administration of tamsulosin hydrochloride to pregnant rabbits at dose levels up to 50 mg/kg/day produced no evidence of fetal harm. tamsulosin hydrochloride capsules are not indicated for use in women. tamsulosin hydroch

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - tamsulosin hydrochloride (unii: 11sv1951mr) (tamsulosin - unii:g3p28oml5i) - tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph) [see clinical studies (14)] . tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension. tamsulosin hydrochloride capsules are contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of tamsulosin hydrochloride capsules. reactions have included skin rash, urticaria, pruritus, angioedema, and respiratory symptoms [see adverse reactions (6.2)]. teratogenic effects, pregnancy category b. administration of tamsulosin hydrochloride to pregnant female rats at dose levels up to approximately 50 times the human therapeutic auc exposure (300 mg/kg/day) revealed no evidence of harm to the fetus. administration of tamsulosin hydrochloride to pregnant rabbits at dose levels up to 50 mg/kg/day produced no evidence of fetal harm. tamsulosin hydrochloride capsules are not indicated for use in women. tamsulosin hydroch

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - furosemide 500mg;   - tablet - 500 mg - active: furosemide 500mg   excipient: colloidal silicon dioxide lactose magnesium stearate maize starch maltodextrin - frusemide in a high-dosage formulation such as urex forte (500 mg tablets) is intended exclusively for patients with severely impaired renal function. for use under strict medical supervision only within a hospital setting. high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function e.g. in chronic glomerulonephritis, lupus erythematous and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l/day dialysis has to be used.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 11.4mg equivalent to atomoxetine 10 mg - capsule - 10 mg - active: atomoxetine hydrochloride 11.4mg equivalent to atomoxetine 10 mg excipient: gelatin   starch tekprint black sw-9008 tekprint black sw-9009 titanium dioxide   water   - indicated for the treatment of attention deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 114mg equivalent to atomoxetine 100 mg - capsule - 100 mg - active: atomoxetine hydrochloride 114mg equivalent to atomoxetine 100 mg excipient: gelatin   iron oxide red   iron oxide yellow   starch tekprint black sw-9008 tekprint black sw-9009 titanium dioxide   water   - indicated for the treatment of attention deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 20.5mg equivalent to atomoxetine 18 mg - capsule - 18 mg - active: atomoxetine hydrochloride 20.5mg equivalent to atomoxetine 18 mg excipient: gelatin   iron oxide yellow starch tekprint black sw-9008 tekprint black sw-9009 titanium dioxide   water   - indicated for the treatment of attention deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 28.5mg equivalent to atomoxetine 25 mg - capsule - 25 mg - active: atomoxetine hydrochloride 28.5mg equivalent to atomoxetine 25 mg excipient: gelatin   indigo carmine iron oxide yellow starch tekprint black sw-9008 tekprint black sw-9009 titanium dioxide   water   - indicated for the treatment of attention deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.